Durable Responses Achieved with AM0010.
In a phase Ib trial, a combination of the experimental immunotherapy AM0010, a PEGylated form of the recombinant human cytokine IL10, and the anti-PD-1 checkpoint inhibitor pembrolizumab was well tolerated and effective at controlling tumors in some patients with advanced renal cell carcinoma, non-small cell lung cancer, and melanoma.
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D018572:Disease-Free Survival; D006801:Humans; D016753:Interleukin-10 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016896:Treatment Outcome
C000622455:AM0010; D061067:Antibodies, Monoclonal, Humanized; D016753:Interleukin-10; D011092:Polyethylene Glycols; C582435:pembrolizumab